Search academic texts

Information × Registration Number 0213U000077, 0110U002890 , R & D reports Title Investigate violations of regulatory and effector component of the immune system in malignant brain tumors and to develop methods of correcting immunotropic drugs popup.stage_title Head Lisyaniy Nicolay, Registration Date 16-01-2013 Organization SI "Institute of Neurosurgery named after acad. A.Romodanov, AMS of Ukraine" popup.description2 The object of the study were immunocompetent cells, CNS tumors human glioma tumor cells, strain 101.8, immunotropic drugs, biological factors of embryonic cells. Objective - to determine the status and features of the interaction of three parts (Th-1, Th-2, Th-3 ) specific antitumor immune response depending on the degree of malignancy of brain tumors and to study in vitro and in experimental antitumor activity of immunomodulatory drugs and humoral factors of embryonic cells. Methods: immunological, pathomorphological, experimentical. Results. Established changing content CD4 + and CD4 + CD25 + immunoregulatory cells, B cells, the level СIC and cytotoxic activity of mononuclear cells in peripheral blood neyrocancer patients, depending on the degree of malignancy of gliomas, varying degrees of infiltration of gliomas CD4 + and CD4 + CD25 + lymphocytes and increased the proportion of CD4 + CD25 + regulatory T cells among CD4 + lymphocytes that infiltrate the tumor with malignant glioma course; different levels of fixed and circulating antibodies to autoantigens these tumors, which depends on the histological features of tumors and the degree of malignancy; production by mononuclear cells that infiltrate glioma cells and gliomas suppressive and proinflammatory cytokines; inhibition of the proliferative response of peripheral blood lymphocytes donor humoral factors in malignant gliomas. In experimental studies received prolong life in rats with experimental gliomas when administered erbisol ultrafarma and immunomodulator galavit. In tests in vitro and in culture tumor cells established cytotoxic effect of immunomodulators class erbisol and galavit. Eestablished data on the state of immunological processes in patients with gliomas and galavit erbisol impact on CNS tumors can be used to develop new approaches to immunotherapy in treatment neyrocancer patients. Product Description popup.authors Бєльська Людмила Миколаївна Главацький Олександр Яковлевич Гнєдкова Ірина Олександрівна Голярник Наталія Олександрівна Ключнікова Антоніна Іванівна Лісяний Микола Іванович Лісяний Олександр Миколайович Маркова Ольга Володимирівна Потапова Антоніна Гнатовна Розуменко Володимир Давидович Семенова Віра Михайлівна Стайно Лариса Петрівна Станецька Діана Миколаївна popup.nrat_date 2020-04-02 Close